Psychedelics Depression

FDA moves to fast-track psychedelic drugs

FDA grants quick review for 3 psychedelic drug trials

The Food and Drug Administration on Friday granted a quick review of three experimental psychedelic drugs meant to treat major depression and post-traumatic stress disorder.

· 1d · on MSN

The FDA just fast-tracked psychedelic drugs to treat depression. They could be here by this summer

Morning Overview on MSN · 38m

FDA to fast-track reviews of 3 psychedelic drugs after Trump directive

· 1d

New drug research could help those with depression

The Food and Drug Administration (FDA) announced Friday it will fast-track reviews of three separate psychedelic drugs to treat mental health conditions like depression.

· 1d

FDA moves to fast-track review of 3 psychedelic drug studies

· 2d

FDA plans ultra-fast review of three psychedelic drugs following Trump directive

1don MSN

The FDA is psyched on psychedelics. Which ones will be studied and why?

After an executive order, the FDA announced it would prioritize the study of some psychedelic drugs for therapeutic use. Which did they choose and why?

Scientific American

RFK, Jr., says ibogaine holds unprecedented promise for treating depression. Here’s what the science says

At a Senate hearing on Wednesday, Robert F. Kennedy, Jr., referred to ibogaine as the most promising treatment for PTSD and depression “that anybody’s ever seen.” Does the science hold that up?

Hosted on MSN

FDA fast-tracks psychedelics for depression, PTSD, alcoholism

The FDA has granted priority review vouchers to accelerate psilocybin and methylone for depression and PTSD, and approved the first U.S. trial of ibogaine derivative noribogaine for alcohol use disorder. The move follows an executive order from President ...

What Is Ibogaine? How Psychedelic Could Help Treat Veterans’ Depression

Trump said on Saturday the directive would “dramatically accelerate” access to research and potential treatments.